More on FBIOP
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $20.06 |
|
|||
| Open | $20.06 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $20.13 | ||||
| Day Low | $19.92 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 10,275 | ||||
- Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
- Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
- Fortress Biotech unit to sell rare disease voucher for $205 million
- UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
- Fortress Biotech unit begins phase 3 dotinurad gout trials
- Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout
- Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
- Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Entities mentioned with FBIOP
- Definitive Agreement | View Related Stories »
- Dividend | View Related Stories »
- PDUFA | View Related Stories »
- FDA | View Related Stories »
- ThinkEquity | View Related Stories »
- Earnings | View Related Stories »
- S3 | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
